Education
About Us
Working with TipRanks
Follow Us
Aquestive Therapeutics (AQST)
NASDAQ:AQST
AQST Analyst Ratings
Strong Buy
8 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
AQST Stock 12 Month Forecast
Average Price Target
$10.29
▲(67.86% Upside)
| Highest Price Target$15.00 | Average Price Target$10.29 | Lowest Price Target$8.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TR | OpenAI - 4o
$7→$6
Hold
-2.12%
Downside
Reiterated
11/06/25
AI Generated ArticleAI Generated Article
LifeSci Capital
$10→$11
Buy
79.45%
Upside
Reiterated
11/06/25
Positive Outlook for Aquestive Therapeutics: Buy Rating Driven by Strong Pipeline, Financial Position, and Upcoming PDUFA DateAQST reported its 3Q25 with EPS of ($0.14) mostly in line with our esmated ($0.15) and the Street's ($0.13). As we look forward to Anaphylm's 1/31/26 PDUFA, we remain encouraged by the company's acve FDA engagement, and sll believe the path to Anaphylm's potenal approval appears clearer, especially without an AdCom. With a robust data package demonstrang rapid absorpon (T max 12 mins), injectable-comparable PK, and a highly convenient sublingual film (vs currently available medical devices), we believe Anaphylm is well- posioned for approval and commercial success (affirmed by our KOL checks). The company connues to make strides in its US commercial readiness efforts including commercial hires, and leadership transions. In AQST's pipeline, AQST-108 alopecia areata program remains on track, with the recently joined Davis leading development efforts.
Citizens JMP
$9→$12
Buy
95.76%
Upside
Reiterated
10/09/25
H.C. Wainwright
$10
Buy
63.13%
Upside
Reiterated
09/17/25
Oppenheimer
$7→$8
Buy
30.51%
Upside
Reiterated
09/08/25
Lake Street
$8
Buy
30.51%
Upside
Reiterated
09/04/25
Leerink Partners
―
Buy
―
Reiterated
09/04/25
Aquestive Therapeutics: De-risking and Strategic Positioning for Success in the Type 1 Allergy MarketWe are not surprised that the stock is up ~20% in early trading on this positive regulatory development. Combined with management's recent financing activities that we believe position them well for a potential commercial launch, we see this no-AdCom decision as further validation of Anaphylm's robust clinical dataset and differentiated profile in the Type 1 allergy market. We continue to believe that management has executed well on de-risking both the regulatory pathway and balance sheet positioning ahead of the key PDUFA milestone, and reiterate that the T1A market should accommodate multiple no-needle epinephrine solutions alongside traditional autoinjectors. Reit. OP.
Piper Sandler
$5
Buy
-18.43%
Downside
Reiterated
08/26/25
Cantor Fitzgerald
$15
Buy
144.70%
Upside
Reiterated
08/19/25
Raymond James
$7
Buy
14.19%
Upside
Reiterated
06/17/25
Alliance Global Partners
$4.75
Buy
-22.51%
Downside
Reiterated
05/14/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TR | OpenAI - 4o
$7→$6
Hold
-2.12%
Downside
Reiterated
11/06/25
AI Generated ArticleAI Generated Article
LifeSci Capital
$10→$11
Buy
79.45%
Upside
Reiterated
11/06/25
Positive Outlook for Aquestive Therapeutics: Buy Rating Driven by Strong Pipeline, Financial Position, and Upcoming PDUFA DateAQST reported its 3Q25 with EPS of ($0.14) mostly in line with our esmated ($0.15) and the Street's ($0.13). As we look forward to Anaphylm's 1/31/26 PDUFA, we remain encouraged by the company's acve FDA engagement, and sll believe the path to Anaphylm's potenal approval appears clearer, especially without an AdCom. With a robust data package demonstrang rapid absorpon (T max 12 mins), injectable-comparable PK, and a highly convenient sublingual film (vs currently available medical devices), we believe Anaphylm is well- posioned for approval and commercial success (affirmed by our KOL checks). The company connues to make strides in its US commercial readiness efforts including commercial hires, and leadership transions. In AQST's pipeline, AQST-108 alopecia areata program remains on track, with the recently joined Davis leading development efforts.
Citizens JMP
$9→$12
Buy
95.76%
Upside
Reiterated
10/09/25
H.C. Wainwright
$10
Buy
63.13%
Upside
Reiterated
09/17/25
Oppenheimer
$7→$8
Buy
30.51%
Upside
Reiterated
09/08/25
Lake Street
$8
Buy
30.51%
Upside
Reiterated
09/04/25
Leerink Partners
―
Buy
―
Reiterated
09/04/25
Aquestive Therapeutics: De-risking and Strategic Positioning for Success in the Type 1 Allergy MarketWe are not surprised that the stock is up ~20% in early trading on this positive regulatory development. Combined with management's recent financing activities that we believe position them well for a potential commercial launch, we see this no-AdCom decision as further validation of Anaphylm's robust clinical dataset and differentiated profile in the Type 1 allergy market. We continue to believe that management has executed well on de-risking both the regulatory pathway and balance sheet positioning ahead of the key PDUFA milestone, and reiterate that the T1A market should accommodate multiple no-needle epinephrine solutions alongside traditional autoinjectors. Reit. OP.
Piper Sandler
$5
Buy
-18.43%
Downside
Reiterated
08/26/25
Cantor Fitzgerald
$15
Buy
144.70%
Upside
Reiterated
08/19/25
Raymond James
$7
Buy
14.19%
Upside
Reiterated
06/17/25
Alliance Global Partners
$4.75
Buy
-22.51%
Downside
Reiterated
05/14/25
Best Analysts Covering Aquestive Therapeutics
1 Month
xxx
Success Rate
12/17 ratings generated profit
Average Return
+11.99%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 70.59% of your transactions generating a profit, with an average return of +11.99% per trade.
3 Months
xxx
Success Rate
11/17 ratings generated profit
Average Return
+23.34%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 64.71% of your transactions generating a profit, with an average return of +23.34% per trade.
1 Year
Success Rate
15/17 ratings generated profit
Average Return
+67.87%
reiterated a buy rating 2 months ago
Copying Roanna Ruiz's trades and holding each position for 1 Year would result in 88.24% of your transactions generating a profit, with an average return of +67.87% per trade.
2 Years
xxx
Success Rate
17/17 ratings generated profit
Average Return
+94.88%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +94.88% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
AQST Analyst Recommendation Trends
Rating
Jul 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
11
9
9
9
6
Buy
3
4
3
2
1
Hold
11
9
10
9
6
Sell
1
0
0
0
0
Strong Sell
0
0
0
0
0
total
26
22
22
20
13
Each month's total comprises the sum of three months' worth of ratings.
AQST Financial Forecast
AQST Stock Forecast FAQ
What is AQST’s average 12-month price target, according to analysts?
Based on analyst ratings, Aquestive Therapeutics’s 12-month average price target is 10.29.
What is AQST’s upside potential, based on the analysts’ average price target?
Aquestive Therapeutics has 67.86% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is AQST a Buy, Sell or Hold?
Aquestive Therapeutics has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.
What is Aquestive Therapeutics’s price target?
The average price target for Aquestive Therapeutics is 10.29. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $15.00 ,the lowest forecast is $8.00. The average price target represents 67.86% Increase from the current price of $6.13.
The highest analyst price target is $15.00 ,the lowest forecast is $8.00. The average price target represents 67.86% Increase from the current price of $6.13.
What do analysts say about Aquestive Therapeutics?
Aquestive Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
How can I buy shares of AQST?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.